763 related articles for article (PubMed ID: 19049391)
1. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport.
Eckford PD; Sharom FJ
Biochemistry; 2008 Dec; 47(51):13686-98. PubMed ID: 19049391
[TBL] [Abstract][Full Text] [Related]
2. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.
Romsicki Y; Sharom FJ
Biochemistry; 1999 May; 38(21):6887-96. PubMed ID: 10346910
[TBL] [Abstract][Full Text] [Related]
3. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
Shen X; Chen G; Zhu G; Fong WF
Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
[TBL] [Abstract][Full Text] [Related]
4. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
5. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors.
Eckford PD; Sharom FJ
Biochem Cell Biol; 2006 Dec; 84(6):1022-33. PubMed ID: 17215888
[TBL] [Abstract][Full Text] [Related]
7. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
Liu R; Sharom FJ
Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
[TBL] [Abstract][Full Text] [Related]
8. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
9. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.
Ramachandra M; Ambudkar SV; Chen D; Hrycyna CA; Dey S; Gottesman MM; Pastan I
Biochemistry; 1998 Apr; 37(14):5010-9. PubMed ID: 9538020
[TBL] [Abstract][Full Text] [Related]
10. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
11. Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism.
Zhang M; Wang G; Shapiro A; Zhang JT
Biochemistry; 1996 Jul; 35(30):9728-36. PubMed ID: 8703944
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity.
Pawagi AB; Wang J; Silverman M; Reithmeier RA; Deber CM
J Mol Biol; 1994 Jan; 235(2):554-64. PubMed ID: 7904655
[TBL] [Abstract][Full Text] [Related]
13. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol.
Kimura Y; Kioka N; Kato H; Matsuo M; Ueda K
Biochem J; 2007 Jan; 401(2):597-605. PubMed ID: 17029589
[TBL] [Abstract][Full Text] [Related]
14. Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study.
Romsicki Y; Sharom FJ
Biochemistry; 1997 Aug; 36(32):9807-15. PubMed ID: 9245413
[TBL] [Abstract][Full Text] [Related]
15. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids.
Eckford PD; Sharom FJ
Biochem J; 2005 Jul; 389(Pt 2):517-26. PubMed ID: 15799713
[TBL] [Abstract][Full Text] [Related]
16. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
Chen Y; Pant AC; Simon SM
Cancer Res; 2001 Nov; 61(21):7763-9. PubMed ID: 11691790
[TBL] [Abstract][Full Text] [Related]
18. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells.
Regev R; Assaraf YG; Eytan GD
Eur J Biochem; 1999 Jan; 259(1-2):18-24. PubMed ID: 9914470
[TBL] [Abstract][Full Text] [Related]
19. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
20. P glycoprotein and the mechanism of multidrug resistance.
Váradi A; Szakács G; Bakos E; Sarkadi B
Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
